The Short List: Current Top 10 Most Shorted Stocks
Reasons for Short Selling: Traders short stocks to either bet on a decline in value or to profit from potential short squeezes, where rising prices force short sellers to buy back shares, creating a feedback loop of increasing demand.
Characteristics of Heavily Shorted Stocks: Stocks become heavily shorted when experienced traders believe they are overvalued, indicating serious risks, while retail traders may see high short interest as an opportunity for quick gains.
Top Heavily Shorted Stocks: As of November 26, 2025, the most shorted stocks include The Wendy's Co. (WEN) at 55.36% short interest, followed by Cambium Networks Corp. (CMBM) and Lucid Group, Inc. (LCID).
Risks and Volatility: While short squeezes can lead to significant gains, they come with high risks and volatility, necessitating careful monitoring and due diligence by traders.
Get Free Real-Time Notifications for Any Stock
Analyst Views on NTLA
About NTLA
About the author

FDA Lifts Clinical Hold on Intellia's IND for ATTRv-PN Trial
- Clinical Hold Lifted: The FDA lifted the clinical hold on Intellia Therapeutics' MAGNITUDE-2 Phase 3 trial, allowing the company to proceed with its investigational new drug application for hereditary transthyretin amyloidosis (ATTRv-PN), which is expected to positively impact future R&D progress.
- Increased Enrollment Target: Intellia has raised the target enrollment for the MAGNITUDE-2 trial from approximately 50 to 60 patients, aiming to enhance the reliability of study results and bolster market confidence in its treatment approach.
- Positive Efficacy Data: In the ongoing Phase 1 study, patients receiving a one-time dose of 0.3 mg/kg or higher (n=33) showed a 92% mean reduction in serum TTR levels at 24 months, indicating the long-term efficacy of nexiguran ziclumeran, which may boost investor confidence in Intellia.
- Enhanced Safety Monitoring: Intellia has agreed with the FDA to implement enhanced safety monitoring measures for liver laboratory tests in the MAGNITUDE-2 trial, addressing previous safety events and providing stronger safety assurances for future clinical trials.

FDA Lifts Clinical Hold on Intellia's Phase 3 Trial
- Clinical Trial Advancement: The FDA has lifted the clinical hold on Intellia's Phase 3 trial for a rare nerve disease following safety updates, marking a significant breakthrough in the company's critical R&D phase and potentially accelerating the path to market.
- Heart Disease Program Review: While the FDA has removed the hold on the Phase 3 trial, the review of Intellia's heart disease program continues, which may impact the company's market entry timeline and strategic positioning in the cardiovascular sector.
- Safety Update Impact: Intellia's safety updates have been recognized by the FDA, indicating effective measures taken to ensure patient safety during trials, which not only boosts investor confidence but may also attract more partners to its R&D initiatives.
- Market Reaction Expectations: With the FDA's positive developments, Intellia's stock price is likely to experience a favorable impact, as investors are optimistic about its future commercial potential and market performance, especially in the competitive landscape of rare disease treatments.









